(atdn) 3tc - a new anti-hiv drug?

AIDS Treatment Data Network (ATDN) 3TC - a new anti-HIV drug?
December 1, 1994

Treatment Review #15; December 1994 3TC, also known as lamivudine, is an antiretroviral that works in the same way as AZT, ddI, ddC and d4T. Researchers studying the drug reported in November of this year that the combination of 3TC and AZT was effective in improving laboratory tests of the immune system. Further trials of the drug to study its clinical benefits will begin next year, the company said. In two separate studies, HIV+ participants were given either AZT, or AZT in combination with 3TC. After 24 weeks, tests showed that study participants taking the combination therapy had an increased number of T cells and lower levels of virus in the blood. The people taking AZT alone either showed less improvement or got worse, according to their laboratory tests. These studies did not examine progression to illness, disease or death, but measured HIV's effects in the blood. People receiving the combination experienced an average gain of 85 T4 cells after eight weeks on study and maintained an increase of 80 T4 cells through week 24. At week 48, an increase of 49 T4 cells persisted. People receiving only AZT had their T4 cell counts drop by an average of seven at week 24. When switched to the combination treatment, these people showed an average increase of 40 T4 cells by week 48. 3TC is in Phase III trials in Europe and the Far East as a treatment for hepatitis B. Phase III trials are planned for the US, Canada and Japan in late 1994 and 1995. Side-effects seen in trials are fatigue and headaches. The company that makes the drug will file for approval of 3TC in the first half of 1995. The company expects to report results from two United States trials comparing AZT, 3TC and the two drugs in combination in late January. With the release of this information, the company's stock surged. Many analysts reacted skeptically, stating, "Popular press overreacts," and pointing out that three other AIDS drugs for use with AZT have already been approved. The data behind the report is based on six months of treatment and six months of follow-up. It is not know how well 3TC in combination with AZT would do if taken for a longer time. Currently, 3TC is in a clinical trial for children and adolescents in combination with AZT and ddI at the National Cancer Institute. If you would like more information about this trial, call The Network. 3TC is also available through an expanded access program from the drug company for both children and adults. Children can take the drug in syrup form. Adults take pills. Doctors can call (800) 248-9757 for more information.

Most Read: Latest Added Related Topics White House LGBT Conference on HIV/AIDS UNITED STATES: White House in Atlanta: LGBT AIDS Conference No more single-theme conferences: global HIV prevention conference planned FHI 360 Senior Scientist Lut Van Damme Receives International Microbicide Conference Lifetime Achievement Award Photographs from A Day with HIV Now Online Equatorial Guinea Ministry of Health and Social Welfare and UNICEF Refute Erroneous AIDS Prevalence Figures Bulgaria urges Libya to investigate AIDS nurses case Engineers enter fight against AIDS in Africa Gilead’s Complera® Non-Inferior to Atripla® Among Treatment-Naive HIV Patients UN chief Ban calls world leaders to end Aids by 2020 ARIZONA: Routine Skin Testing Available Again at Tuberculosis Clinic Starting May 20 NORTH DAKOTA: Officials: 26 Tuberculosis Cases from Grand Forks Outbreak AUSTRALIA: HIV Rates Triple in the Northern Territory in Just 12 Months ARIZONA: Parsons Foundation Gives $3 Million to Southwest Center for HIV/AIDS UNITED STATES: Triple Therapy for Hepatitis C is Effective After Liver Transplantation, but Side-Effects Are Common CANADA: Nunavut Uses Comic Book to Do Sex Education NEW HAMPSHIRE: State Health Officials Urge Hepatitis Testing UNITED STATES: Hepatitis C Testing for People Born Between 1945 and 1965 People with HIV pay more for life insurance – if they can get it (South Africa)Uganda: Gov't Urged to Levy a Tax On Alcohol to Fund HIV AUSTRALIA: HIV Rates Triple in the Northern Territory in Just 12 Months ARIZONA: Parsons Foundation Gives $3 Million to Southwest Center for HIV/AIDS NEW HAMPSHIRE: State Health Officials Urge Hepatitis Testing People with HIV pay more for life insurance – if they can get it (South Africa)Uganda: Gov't Urged to Levy a Tax On Alcohol to Fund HIV No time to lose in the search for an HIV vaccine Russia has 'no anti-AIDS strategy': official 1 new hepatitis case in Okla. public health scare Health group didn't disclose HIV tests, apologizes NEW JERSEY: Drug Company Donates Thousands to HIV/AIDS Orgs
Copyright © 1994 -AIDS Treatment Data Network, Publisher. All rights reserved to AIDS Treatment Data Network. Reproduction of this article (other than one copy for personal reference) must be cleared through the AIDS Treatment Data Network. Email AIDS Treatment Data Network Information in this article was accurate in December 1, 1994. The state of the art may have changed since the publication date. This material is designed to support, not replace, the relationship that exists between you and your doctor. Always discuss treatment options with a doctor who specializes in treating HIV.